Parkinson Disease

Epigenic Therapeutics and NRG Therapeutics Each Secure ~$60M in Series B Rounds for Epigenetic and Neuroscience Advances

2 days ago talkbio0Tagged Amyotrophic Lateral Sclerosis, Biotechnology, epigenetic therapy, Epigenic, Gene Silencing, Hepatitis B, Hypercholesterolemia, Investments, NRG, Parkinson Disease, Series B funding

Epigenic Therapeutics; NRG Therapeutics; Series B funding; epigenetic therapy; hepatitis B; hypercholesterolemia; Parkinson’s disease; ALS; biotechnology investment; gene silencing

AC Immune Narrows Pipeline and Cuts 30% Workforce to Extend Cash Runway

6 days ago talkbio0Tagged Actinium, Alzheimer 's disease, cash runway, Immune, late-stage assets, layoffs, Parkinson Disease, pipeline reduction

AC Immune; pipeline reduction; layoffs; cash runway; biotech; Alzheimer’s disease; Parkinson’s disease; late-stage assets; workforce reduction

FDA Approves Vyalev: A Breakthrough Continuous Infusion Therapy for Advanced Parkinson’s Disease

11 months ago talkbio0Tagged AbbVie, Approved, carbidopa, Continuous, Infusion procedures, levodopa, motor fluctuations, Parkinson Disease, United States Food and Drug Administration, Vyalev

Vyalev, Parkinson’s disease, continuous infusion therapy, FDA approval, AbbVie, motor fluctuations, levodopa, carbidopa

MeiraGTx Announces Positive Phase 2 Data for AAV-GAD Gene Therapy in Parkinson’s Disease, Paving Way for Phase 3 Trial

11 months ago talkbio0Tagged AAV-GAD, gene therapy, Genetic Medicine, MeiraGTx, Neurodegenerative Disorders, Parkinson Disease, Phase 2 trial, Phase 3 trial

MeiraGTx, AAV-GAD, Gene Therapy, Parkinson’s Disease, Phase 2 Trial, Phase 3 Trial, Neurodegenerative Disorders, Genetic Medicine